Full Press Release Details
Zenas BioPharma Submits Investigational New Drug Application in China for ZB001 for the Treatment of Thyroid Eye Disease.
ZBIO
Zenas BioPharma Submits Investigational New Drug Application in China for ZB001 for the Treatment of Thyroid Eye Disease
Key Takeaway: Zenas BioPharma Submits Investigational New Drug Application in China for ZB001 for the Treatment of Thyroid Eye Disease
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceBest trade, last catalyst
+116%
120-day peak, hindsight
Typical move
8.9%
average across 3 past catalysts
Cash runway
~33 mo
Minimal dilution risk
Lead asset
Orelabrutinib
Phase 3 · Multiple Sclerosis (MS) Primary Progressive